MODULE 3

Patient Preference Data

Discover how to harness Patient Preference Data (PPD) to improve healthcare decision-making. Explore methodologies to capture patient insights, guide clinical trials, and influence regulatory frameworks.
What you are going to learn

Master Patient
Preference Data

Unlock the potential of patient insights to transform healthcare decisions and drive innovation.
  • Understand the difference between Patient Preference Data and Patient-Reported Outcome (PRO) measures.
  • Design effective studies using qualitative and quantitative research methods.
  • Analyse patient preferences to enhance clinical development and regulatory decision-making.
  • Navigate challenges and explore future applications of Patient Preference Data in healthcare.

Self -paced

Take the whole course or select from the topics most relevant to you. 

Beginner - Intermediate 

This training is a valuable resource for patients,  professionals and advocates involved in healthcare decision-making.

Learn from experts

This course was developed through the collaboration of diverse stakeholders, including patient advocates, researchers, clinicians, representatives of HTA bodies, regulatory authorities, and industry professionals.

Detailed Course Contents

Course reviews

Excellent course! The insights into designing effective preference studies have already improved our research projects, making them more patient-centered and impactful.
This course provided a comprehensive understanding of Patient Preference Data. I've gained valuable skills to enhance clinical decision-making and patient engagement.
This course empowered me as a patient advocate by providing the skills to ensure patient preferences are prioritized in healthcare decisions.
This WECAN Training Program on Patient Experience Data was initiated in 2023 as part of the WECAN Academy.
Funding for the course was administered by the European Patient Advocacy Institute (EPAI) gUG Germany and was obtained from industry and non-industry funders that included Biomarin, Bristol Myers Squibb, Boehringer Ingelheim, Rising Tide Foundation for Clinical Cancer Research, Roche, Servier and Takeda.
The funders had no role in the course development.